As Uganda rolls out mandatory nationwide screening of newborns for sickle cell disease this month, a gene therapy celebrated in the United States and Europe remains financially out of reach for most ...
After a turbulent 2025, the biopharma industry is heading into the new year with major questions still unresolved. A tough biotech investing environment, aggressive direct-to-consumer drug marketing ...
While policy shifts and leadership shakeups at institutions like the Food and Drug Administration dominated headlines in 2025, drugmakers would do well to sift through the noise and remain focused on ...
As we conclude a successful 2025, I want to extend my appreciation for your continued support of Lineage Cell Therapeutics and our mission to pioneer the emerging field of allogeneic cell therapy. I ...
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Lineage Cell Therapeutics, Inc. before investing. In this article, we go over a ...
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in rare metabolic diseases. The drugmaker will pay $14.50 per share for ...
Fintel reports that on November 24, 2025, HC Wainwright & Co. maintained coverage of Lineage Cell Therapeutics (NYSEAM:LCTX) with a Buy recommendation. As of November 17, 2025, the average one-year ...
CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — Lineage Cell Therapeutics, Inc. (LCTX) on Thursday reported a loss of $29.8 million in its third quarter. The Carlsbad, California-based company said it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results